Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Autor: | Jos H. Beijnen, Jan H.M. Schellens, Laurens E Swart, Alwin D. R. Huitema, Neeltje Steeghs, Remy B. Verheijen |
---|---|
Přispěvatelé: | Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
Rok vydání: | 2017 |
Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Dose opimization Population Toxicology 030226 pharmacology & pharmacy Pazopanib 03 medical and health sciences Cmin 0302 clinical medicine Renal cell carcinoma Internal medicine Journal Article medicine Humans Pharmacokinetics Pharmacology (medical) Progression-free survival education Carcinoma Renal Cell Aged Pharmacology Sulfonamides Soft tissue sarcoma education.field_of_study business.industry Carcinoma Renal Cell Cancer Sarcoma Middle Aged medicine.disease Survival Analysis Personalized medicine Pyrimidines Treatment Outcome 030220 oncology & carcinogenesis Original Article Female business Dose optimization medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology, 80(6), 1171. Springer Verlag Cancer Chemotherapy and Pharmacology |
ISSN: | 1432-0843 0344-5704 |
DOI: | 10.1007/s00280-017-3463-x |
Popis: | BACKGROUND: Pazopanib is an angiogenesis inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Post hoc analysis of a clinical trial demonstrated a relationship between pazopanib trough concentrations (Cmin) and treatment efficacy. The aim of this study was to explore the pharmacokinetics and exposure-survival relationships of pazopanib in a real-world patient cohort. PATIENTS AND METHODS: Renal cell cancer and soft tissue sarcoma patients who had at least one pazopanib plasma concentration available were included. Using calculated Cmin values and a threshold of > 20 mg/L, univariate and multivariate exposure-survival analyses were performed. RESULTS: Sixty-one patients were included, of which 16.4% were underexposed (mean Cmin 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142). In multivariate analysis Cmin > 20 mg/L was associated with hazard ratios of 0.25 (p = 0.021) in renal cancer, 0.12 (p = 0.011) in sarcoma and 0.38 (p = 0.017) in a pooled analysis. CONCLUSION: This study confirms that pazopanib Cmin > 20 mg/L relates to better progression free survival in renal cancer and points towards a similar trend in sarcoma patients. Cmin monitoring of pazopanib can help identify patients with low Cmin for whom individualized treatment at a higher dose may be appropriate. |
Databáze: | OpenAIRE |
Externí odkaz: |